Hyderabad becomes second largest base of pharmaceutical company Novartis: Minister

Hyderabad, May 24 (UNI) Telangana Minister of Information Technology and Industries, KT Rama Rao, says Hyderabad has become the second largest base for pharmaceutical company Novartis after its headquarters in Basel, Switzerland, based on the workforce.

The Novartis Capability Center here has nearly 9,000 associates, Rao said after meeting Vasant Narasimhan, chief executive of Novartis on the sidelines of the World Economic Forum (WEF) in Davos on Tuesday to discuss the pharmaceutical company’s growth in Telangana and its expansion plans. .

Novartis is a Swiss multinational pharmaceutical company based in Basel and one of the largest pharmaceutical companies in the world.

Novartis Capability Center in Hyderabad is the largest of a major global pharmaceutical company in India.

Novartis’ growth in the city is driven by a focus on innovation and the center has become an important innovation hub for the company.

Incidentally, the company had also chosen Hyderabad as the APAC hub for its innovation initiative called Biome which focuses on several new key innovative areas such as AI, data and digital.

The company continues to leverage Hyderabad’s rich capabilities in the science, technology and innovation ecosystem to drive business-relevant business.

Novartis’ growth in Hyderabad is a testament to Hyderabad’s growing R&D prowess and extraordinary talent pool.

Hyderabad today serves more than 1000 global innovators in their vision to improve healthcare and research and development worldwide.

Rama Rao said, “I am extremely proud that Hyderabad has become Novartis’ largest global hub outside of its headquarters. With a massive staff of 9,000, I’m really impressed with the type of cutting-edge work – be it data, digital and AI/ML – that takes place at the center.”

Novartis has already put Hyderabad on a global map in the life sciences sector and there could be no better endorsement for the Hyderabad ecosystem, the Minister added.


Comments are closed.